Brian Manases roldan1, Carolina A Isnardi2, Virginia Carrizo Abarza1, Maria Agustina Alfaro1, Tatiana Barbich2, Maria Gisela Crespo Rocha2, Marina Fornaro2, Osvaldo Luis Cerda2, Fernando Dal pra2, Emilce Edith Schneeberger2 and Gustavo Citera2, 1Rheumatology Unit, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina
Background/Purpose: To evaluate the differences in sociodemographic and clinical characteristics, disease activity, functional status and quality of life between male and female patients with PsA.
Methods: Observational cross-sectional study. Patients of≥18 years old with a diagnosis of PsA according to CASPAR criteria were included. Sociodemographic, clinical and therapeutic characteristics, comorbidities, toxic habits and extra-articular manifestations were collected. Presence of dactylitis and enthesitis (MASES) were recorded. Cutaneous psoriasis was assessed by PASI, BSA and nail involvement by PNSS. ESR (mm/h) and CRP (mg/dl) values were recorded. HAQ-A questionnaires for functional capacity and PsAQoL and DLQI for quality of life were administered. Composite indices were calculated: DAPSA and DAPSA-ESR. Additionally, the presence of MDA was determined. Axial involvement was defined by ASAS 2009 criteria. X-rays were read by 3 experienced rheumatologists (CCI: ≥ 0.89) according to Sharp van der Heijde index. Statistical descriptive analysis: Chi² and Fisher's exact test, Student's t-test, Mann Whitney, ANOVA and multiple logistic regression.
Results: A total of 170 patients were included, 50% female, mean (X) age 54.5±13.5 years and mean disease duration was 11.4±9.7 years. Most patients had only peripheral involvement, 88.2% in men and 83.5% in women.Sharp/van der Heijde score was higher in men than in women but this difference was not significant (men X 43.1±75.4 vs women X 37.1±55.8, p=NS).
Regarding disease activity, females presented a higher frequency of enthesitis (31.2% vs 16.5%, p=< 0.0001) and higher DAPSA-ERS (X 17.9±11.9 vs X 14.5±10.5, p=0.048), while males had higher skin involvement (BSA X 6.5±14.3 vs X 3±15.3, p=0.032). Moreover, no significant differences were found in functional capacity (HAQ-A men X 0.92±0.7 vs women 0.72±10.5) and quality of life (PsAQoL men X 6.4±6.5 vs women X 7.2±6.4).
In multivariate analysis, adjusting for age and disease duration, males presented higher skin involvement by BSA (OR 1.05, 95%CI 1.01-1.1), while MASES was lower in this group (OR 0.8, 95%CI 0.73-0.98, p= 0.03).
Conclusion: Women had higher disease activity and entheseal involvement, while men presented greater extension of psoriasis.The entheseal involvement and psoriasis remained significantly associated with gender after adjusting for sociodemographic and clinical variables.
Disclosures: B. roldan, None; C. Isnardi, None; V. Carrizo Abarza, None; M. Alfaro, None; T. Barbich, None; M. Crespo Rocha, None; M. Fornaro, None; O. Cerda, None; F. Dal pra, Pfizer, Abbvie; E. Schneeberger, AbbVie/Abbott, Pfizer, Boehringer-Ingelheim, Janssen, Bristol-Myers Squibb(BMS); G. Citera, AbbVie, Amgen, Bristol Myers Squibb, Gema, Janssen, Pfizer, Sandoz, Boehringer Ingelheim.
